Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1826 - Use of a Cognitive Computing System for Treatment of Cervical Cancer (298P)


18 Nov 2017


Poster lunch


Soyi Lim


Annals of Oncology (2017) 28 (suppl_10): x86-x93. 10.1093/annonc/mdx663


S. Lim, L. Kwang-Beom

Author affiliations

  • Obgy, Gachon University Gil Hospital, 405-760 - Incheon/KR


Abstract 1826


IBM Watson for Oncology (WFO) is a Memorial Sloan Kettering Cancer Center-trained cognitive computing system that uses natural language processing to provide oncologists with ranked, evidence-based treatment options for cancer. We examined the concordance of cervical cancer adjuvant treatment options between WFO and our institute treatment from Gachon University Gil Medical Center (GMC), Incheon, South Korea.


We retrospectively enrolled patients with FIGO stage I to II cervical cancer who underwent surgical treatment between 2006 and 2016. WFO treatment options were considered concordant when the practice was included in the “Recommended” or “For Consideration” categories provided by WFO.


We retrospectively evaluated 496 enrolled patients with FIGO stage I to II cervical cancer who underwent primary surgical treatment between 2006 and 2016. Of them, 9 patients were excluded because they had rare histology, inadequate imaging study, over age-range that covered by WFO or history of neoadjuvant chemotherapy, any one of which is not applicable to WFO. Of them, a total of 117 patients who received adjuvant only chemotherapy was not included in the concordance rate calculation because the GMC practice is unknown treatment option in the WFO. Treatment recommendations were concordant in 299 (80.8%) of the 370 patients: Recommended for 277, and For Consideration for 22.


Treatment options suggested by WFO were concordant with the GMC treatment in the majority of cervical cancer patients. Further analysis is needed.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings